Go Pro
→ The $15 Gold Fund That Pays Up to $1,152/Month (From Investors Alley) (Ad)tc pixel
NASDAQ:KZIA

Novogen Q4 2025 Earnings Report

Novogen logo
$12.16 -0.45 (-3.57%)
As of 09/3/2026 04:00 PM Eastern
ProfileEarnings HistoryForecast

Novogen EPS Results

Actual EPS
-$6.14
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Novogen Revenue Results

Actual Revenue
$0.59 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Novogen Announcement Details

Quarter
Q4 2025
Date
11/7/2025
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Novogen's next earnings date is estimated for Friday, September 4, 2026, based on past reporting schedules.

Conference Call Resources

Novogen Earnings Headlines

Novogen (NASDAQ:KZIA) Stock Price Expected to Rise, BTIG Research Analyst Says
September 3 at 1:48 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30999839
Kazia Therapeutics Reports Preclinical Data Showing Paxalisib Reprograms Immunotherapy-Resistant MSS/pMMR Colorectal Cancer and Enhances Response to Immunotherapy
September 1 at 7:30 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-reports-preclinical-data-showing-paxalisib-reprograms-immunotherapy-resistant-msspmmr-colorectal-cancer-and-enhances-response-to-immunotherapy-302865533.html
How Long Does $2.5M Last in Retirement?
Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you make with it. Using the 4% rule as a benchmark, that balance could translate to about $100,000 in year one, adjusted upward for inflation each year after. But the 4% rule has potential downsides and may not fit every portfolio. A financial advisor can help size and structure a retirement budget around your income sources, taxes, and goals. SmartAsset's free quiz matches nearly 50,000 people each month with vetted fiduciary advisors.tc pixel
 |  SmartAsset (Ad)
Kazia Therapeutics Expands Paxalisib Clinical Trial into HR+/HER2- Breast Cancer, Supported by Preclinical Data Showing Strong Clinical Activity and Safety in HR+ Breast Cancer
September 1 at 7:15 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-expands-paxalisib-clinical-trial-into-hrher2--breast-cancer-supported-by-preclinical-data-showing-strong-clinical-activity-and-safety-in-hr-breast-cancer-302865460.html
Kazia Therapeutics Limited Announces Oversubscribed Closing of Up to $120 Million Public Offering
August 31, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/kazia-therapeutics-limited-announces-oversubscribed-closing-of-up-to-120-million-public-offering-302865390.html
Kazia Therapeutics: Worth Speculating On Paxalisib's TNBC Data
August 31, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4941623-kazia-therapeutics-stock-worth-speculating-paxalisib-tnbc-data
See More Novogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Novogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Novogen and other key companies, straight to your email.

About Novogen

Novogen (NASDAQ:KZIA) (NASDAQ:KZIA) is a clinical-stage biotechnology company focused on the discovery and development of novel small-molecule therapeutics for the treatment of cancer. The company’s pipeline includes GDC-0084, a brain-penetrant phosphoinositide 3-kinase (PI3K) inhibitor in Phase II development for glioblastoma, as well as Cantrixil, an orally bioavailable small molecule designed to target treatment-resistant ovarian cancer stem cells. Novogen’s research efforts leverage structure-based drug design to optimize selectivity and pharmacokinetic profiles, seeking to address high-unmet medical needs in oncology.

Founded in Australia and now headquartered in New York City, Novogen maintains research facilities in Perth and collaborates with academic institutions and contract research organizations worldwide. The company benefits from strategic partnerships and licensing arrangements designed to advance its lead programs through clinical trials while expanding its preclinical pipeline into additional tumor types. Novogen’s global footprint enables access to diverse patient populations and fosters collaborations in neuroscience and oncology research.

Under the leadership of Chief Executive Officer Dr. Daniel Goldstein, Novogen continues to prioritize the rapid development of its clinical candidates through regulatory milestones. The management team combines expertise in medicinal chemistry, clinical development, and regulatory affairs to streamline translational research and engage with key opinion leaders. Through ongoing clinical trials and data readouts, Novogen aims to demonstrate the safety and efficacy of its novel small molecule therapies and to establish strategic partnerships for commercialization.

View Novogen Profile
Earnings Tools